NASDAQ:VRPX Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis $0.0020 0.00 (0.00%) As of 11/6/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Virpax Pharmaceuticals Stock (NASDAQ:VRPX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Virpax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0020▼$0.002050-Day Range$0.00▼$0.1652-Week Range$0.00▼$0.21VolumeN/AAverage Volume1,303 shsMarket Capitalization$2.48 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Virpax Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing non-opioid treatments for pain and disorders of the central nervous system. The company uses drug-delivery technologies intended to improve the administration, duration, and tolerability of established pharmaceutical compounds. Its investigational product pipeline has included Epoladerm, a topical diclofenac formulation being developed for pain associated with osteoarthritis; Probudur, an extended-release liposomal bupivacaine formulation intended for postsurgical pain management; and Envelta, an intranasal formulation of dexmedetomidine being studied for pain and other potential central nervous system applications. Virpax has also evaluated additional product candidates for acute pain, chronic pain, and post-traumatic stress disorder. Virpax was founded in 2014 and is headquartered in West Chester, Pennsylvania. The company’s products remain investigational and are subject to clinical development and regulatory review; its business has primarily centered on research, development, and licensing or collaboration opportunities rather than the sale of approved commercial medicines.AI Generated. May Contain Errors. Read More Receive VRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRPX Stock News HeadlinesVirpax Pharmaceuticals stock plummets on Nasdaq delisting newsApril 3, 2025 | investing.comVirpax Pharmaceuticals Inc trading halted, news pendingMarch 21, 2025 | markets.businessinsider.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 8 at 1:00 AM | Weiss Ratings (Ad)Virpax reports positive results in Probudur dog studyMarch 20, 2025 | investing.comVirpax receives positive Probudur results for dose range studyMarch 20, 2025 | markets.businessinsider.comVirpax Pharmaceuticals announces 1-for-25 reverse stock splitMarch 20, 2025 | markets.businessinsider.comVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDMarch 18, 2025 | finance.yahoo.comVirpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 18, 2025 | markets.businessinsider.comSee More Headlines VRPX Stock Analysis - Frequently Asked Questions How have VRPX shares performed this year? Virpax Pharmaceuticals' stock was trading at $0.0111 at the beginning of the year. Since then, VRPX shares have decreased by 82.0% and is now trading at $0.0020. When did Virpax Pharmaceuticals' stock split? Shares of Virpax Pharmaceuticals reverse split on Friday, March 1st 2024.The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virpax Pharmaceuticals IPO? Virpax Pharmaceuticals (VRPX) raised $20 million in an initial public offering (IPO) on Wednesday, February 17th 2021. The company issued 1,800,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of Virpax Pharmaceuticals? Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virpax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include Tonix Pharmaceuticals (TNXP), NRx Pharmaceuticals (NRXP), Vaxart (VXRT), Bank of America (BAC), Aclaris Therapeutics (ACRS), Aldeyra Therapeutics (ALDX) and Ardelyx (ARDX). Company Calendar Today11/08/2026Next Earnings (Estimated)11/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VRPX CIK1708331 Webwww.virpaxpharma.com Phone610-727-4597FaxN/AEmployees7Year Founded2017Profitability EPS (Trailing Twelve Months)($123.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.19 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,554.34% Return on Assets-338.29% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book0.00Miscellaneous Outstanding Shares1,242,000Free Float4,707,000Market Cap$2.48 thousand OptionableNot Optionable Beta-201.59 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:VRPX) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredA monthly income idea that does not require selling sharesA $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
